The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data
Open accessAbstract
ypertension is a major risk factor for cardiovascular and cerebrovascular disease.The World Health Organization Global Burden of Disease Study estimates that nonoptimal blood pressure [(BP) ie, systolic BP of Ͼ115 mm Hg] is responsible annually for 7.1 million deaths and the loss of 64.3 disability-adjusted life years worldwide.1 The associated economic burden of hypertension is also substantial.The average annual medical care cost for individuals with hypertension has been estimated at $3900 (in year 2000 US dollars) in Canada, 2 with similar values ($3787) for the United States.3 The increase in medical care costs is greater for those with moderate-to-severe BP elevation (diastolic BP Ͼ104 mm Hg) than for those with mild disease.4 Although a broad range of hypertension medications have been demonstrated to reduce BP, and BP control is an achievable goal, 5 reports suggest that up to two thirds of patients with hypertension are not successfully treated, that is, achieve BP control.6 -8 According to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), BP control rates are far below the "healthy people" goal of 50% set in 2000.9 A major (and modifiable) reason for lack of BP control is failure by patients to use medications as prescribed.10 Appropriate use of medications includes compliance, taking medications at the prescribed frequency/ interval and dose/dosing regimen, and persistence, continuing their use for the specified treatment time period, which, in the case of hypertension therapy, is usually lifelong.11 Poor compliance with hypertension medications is associated with adverse health outcomes.12 Studies have demonstrated that poor BP control is associated with greater healthcare costs.13 For example, in the United States, inadequate control of hypertension has been estimated to result in Ϸ40 000 cardiovascular events, Ͼ8000 cardiovascular disease deaths, and approximately $964 million in direct medical expenditures.14 Similarly, poor compliance and lack of persistence with BP medications are associated with increased health care costs.15,16 Whereas patients who interrupted hypertension therapy had decreased medication costs, they had greater increases in costs for other health care, mainly reflecting increased hospital costs.17 In other disease states, such as diabetes and hypercholesterolemia, whereas increased compliance is associated with increased medication costs (because compliant patients use more medication), overall health care costs decrease because of better disease control and lower rates of adverse outcomes.18 Compliance and persistence can be measured in both retrospective and prospective studies, both of which can provide data on "real world" clinical practice.However, participants in prospective evaluations may not be comparable to broader patient populations.Furthermore, prospective evaluations can potentially introduce biases, particularly in patient behaviors related to compliance and persistence.Although the use of retrospective databases avoids these problems, the lack of consistent methods for evaluation of hypertension treatment compliance and persistence in such studies makes comparisons of results among studies difficult.As presented in a review by Lopatriello et al,19 this lack of standardization in study design, population, and methods can produce tremendous variations in reported compliance with hypertension therapy.In addition, the lack of broadly agreed-on methods creates substantial barriers for evaluating the potential impact of compliance and persistence on BP control.Given the importance of this issue, we have developed a set of recommendations for retrospective studies assessing compliance and persistence in hypertension. Importance of Hypertension Therapy Compliance and Persistence in Medical PracticeNoncompliance is usually considered as missing medication doses in the context of ongoing use, whereas nonpersistence refers to premature discontinuation of treatment.Although compliance and persistence are both components of appropriate medication use, they have differing implications for medical practice.Lack of persistence often occurs when patients discontinue therapy without instructions from or
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729
Rizzo, J. A., & Robert Simons, W. (1997) · Clinical Therapeutics · doi:10.1016/s0149-2918(97)80018-5 · Cited by 174
Taylor, A. A., & Shoheiber, O. (2003) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2003.03269.x · Cited by 151
Cited by
A new taxonomy for describing and defining adherence to medications
Vrijens, B., De Geest, S., Hughes, D. A., Przemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., et al. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04167.x · Cited by 2,028
Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009) · Circulation · doi:10.1161/circulationaha.108.768986 · Cited by 1,488
Adherence in Hypertension: A Review of Prevalence, Risk Factors, Impact, and Management
Burnier, M., & Egan, B. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313220 · Cited by 878
Self-citationVrijens, B., Vincze, G., Kristanto, P., Urquhart, J., & Burnier, M. (2008) · BMJ · doi:10.1136/bmj.39553.670231.25 · Cited by 863
Self-citationCramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A., & Khan, Z. M. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01630.x · Cited by 487
Self-citation
Metadata
- Authors
- Halpern, M. T., Khan, Z. M., Schmier, J. K., Burnier, M., Caro, J. J., Cramer, J., Daley, W. L., Gurwitz, J., & Hollenberg, N. K.
- Venue
- Hypertension
- Published
- 2006-06
- Volume
- 47
- Issue
- 6
- Pages
- 1039-1048
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2139584372
- Cited by
- 189
- References
- 3
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data. https://app.cochat.ai/papers/10.1161/01.hyp.0000222373.59104.3d
- The paper
- Halpern, M. T., Khan, Z. M., Schmier, J. K., Burnier, M., Caro, J. J., Cramer, J., Daley, W. L., Gurwitz, J., & Hollenberg, N. K. (2006). Recommendations for Evaluating Compliance and Persistence With Hypertension Therapy Using Retrospective Data. Hypertension. https://doi.org/10.1161/01.hyp.0000222373.59104.3d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.